General Clinical Chemistry Analyzers and Accessories
Abcam LCL161, 100MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Nanotemper Technologies Inc NanoTemper Technologies SKU: PR-P006, Capillary Remover
Capillary Remover for use with the Prometheus NT.48. The Capillary Remover is designed for removing capillaries from the Prometheus NT.48 instrument after the measurement in one scoop to minimize handling steps.
Abcam P 22077, 50MG
MW 315.3 Da, Purity >98%. Selective USP7 (IC₅₀ = 8 μM) inhibitor. Active against closely related USP47. Selective versus SENP2c0re (IC₅₀ >50 μM) and DENI (IC₅₀ >50 μM). Destabilizes Claspin. Inhibits neuroblastoma growth by inducing p53-mediated apoptosis. Inhibits Tip60 deubiquitination.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 100MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Qstatin, 5MG
MW 293.2 Da, Purity >=98%. A potent, and selective Vibrio QS inhibitor which affects Vibrio harveyi LuxR homologues, the well-conserved master transcriptional regulators for QS in Vibrio species. QStatin binds tightly to a putative ligand-binding pocket in SmcR, the LuxR homologue in V. vulnificus, and changes the flexibility of the protein, thereby altering its transcription regulatory activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 50MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 5MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 50MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Alvespimycin (17-DMAG) hydrochloride, 25MG
MW 653.2 Da, Purity >99%. A potent Hsp90 inhibitor (IC₅₀ = 62 nM), can bind to the ATP-binding motif and inhibit the protein chaperoning activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW 6471, PPAR alpha antagonist, 5MG
MW 619.7 Da, Purity >98%. Potent PPAR alpha antagonist (IC₅₀ = 240 nM). Drives displacement of co-activators from PPAR alpha. Promotes recruitment of co-repressor proteins SMRT and NCoR to ligand binding domain. Inhibits cardiomyocyte differentiation in mouse embryonic stem cells. Causes reduced expression of cardiac sarcomeric proteins and specific genes in a time-dependent manner.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BAY-299, TAF1 and BRD1 inhibitor, 25MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Capivasertib (AZD5363), 100MG
MW 428.9 Da, Purity >95%. A novel pyrrolopyrimidine derivative. A potent inhibitor of all AKT isoforms, IC₅₀ <10 nM, with potential antineoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT1720 hydrochloride, 25MG
MW 506 Da, Purity >=98%. Selective SIRT1 activator (EC₅₀ = 0.16 μM), 230-fold less potent for SIRT2 and SIRT3. Induce autophagy.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 5MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 10MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement